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Background: The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has failed in many ways to be 
as potent in the anti-cancer role as pre-clinical studies would have suggested. This paper traces some aspects of this 
failure to a compensatory erlotinib-mediated increase in interleukin-8. Many other-but not all- cancer chemothera-
peutic cytotoxic drugs also provoke a compensatory increase in a malignant clone’s interleukin-8 synthesis. Untreated 
glioblastoma and other cancer cells themselves natively synthesize interleukin-8. Interleukin-8 has tumor growth 
promoting, mobility and metastasis formation enhancing, effects as well as pro-angiogenesis effects.
Findings: The old sulfone antibiotic dapsone- one of the very first antibiotics in clinical use- has demonstrated 
several interleukin-8 system inhibiting actions. Review of these indicates dapsone has potential to augment erlotinib 
effectiveness. Erlotinib typically gives a rash that has recently been proven to come about via an erlotinib triggered 
up-regulated keratinocyte interleukin-8 synthesis. The erlotinib rash shares histological features reminiscent of typi-
cal neutrophilic dermatoses. Dapsone has an established therapeutic role in current treatment of other neutrophilic 
dermatoses.
Conclusion: Thus, dapsone has potential to both improve the quality of life in erlotinib treated patients by ameliora-
tion of rash as well as to short-circuit a growth-enhancing aspect of erlotinib when used in the anti-cancer role.
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Pancreas cancer, Rash, Quality of life
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Prelude: In chess, all moves create weaknesses and strengths.
Background
This paper points to a simple drug addition to erlotinib 
that is planned to make erlotinib both better tolerated 
and more effective in the anti-cancer role. Erlotinib is a 
393 Da tyrosine kinase inhibitor with specific activity for 
the epidermal growth factor receptor [EGFR] also termed 
HER-1 (Zahonero and Sanchez-Gomez 2014). Rash, diar-
rhea, and fatigue are common side effects (Tiseo et  al. 
2014). The typical erlotinib rash can be quite bothersome 
in a significant minority of those treated, lowering qual-
ity of life (Tiseo et  al. 2014). Erlotinib has been shown 
to prolong overall survival in non-small cell lung can-
cer (D’Arcangelo and Cappuzzo 2013; Pallis and Syrigos 
2013; Zhang et al. 2012) and pancreatic cancer with gem-
citabine (Zahonero and Sanchez-Gomez 2014; Park et al. 
2013; Vaccaro et  al. 2013) or with capecitabine (López 
et  al. 2013), indications for which it is widely used and 
approved by national regulatory authorities. However, in 
pre-treated patients median overall survival (OS) is less 
than a year in both pancreas cancer (Vaccaro et al. 2013; 
López et al. 2013; Stepanski et al. 2013) and in non-small 
cell lung cancer (Van Meerbeeck et  al. 2014; Kaburagi 
et al. 2013).
Good tumor suppressive effects in head and neck can-
cer is typically associated with rash or mucositis in a third 
of treated patients (Gross et al. 2014). Erlotinib has useful 
effects like this in several cancers when used “off-label”, 
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for example, muscle invasive bladder cancer can be sig-
nificantly down-staged after 4  weeks preoperative erlo-
tinib (Pruthi et al. 2010). With erlotinib (plus bevacizumab) 
in advanced platinum-resistant epithelial ovarian cancer 
[EOC] 70 % of patients progressed by 6 months (Chambers 
et  al. 2010). Glioblastoma patients treated at first recur-
rence with erlotinib had a median 10  month overall sur-
vival with 20 % of treated patients experiencing severe rash 
(Yung et al. 2010). When treating recurrent glioblastoma, 
erlotinib at 150 mg daily gives a 3 month progression-free 
survival and 9  month overall survival (Peereboom et  al. 
2010). Recent study of erlotinib with temsirolimus gave no 
better results (Wen et al. 2014). In selected good-prognosis 
post-resection, post-radiation (but never chemotherapy) 
glioblastoma patients, daily erlotinib gave a 3 % non-pro-
gression at 6  months and 40  % death at one year (Raizer 
et  al. 2010). Erlotinib monotherapy in recurrent glioblas-
toma gave a median 7 month OS (Kesavabhotla et al. 2012).
The high incidence of EGFR overexpression in pediatric 
high grade gliomas (Zahonero and Sanchez-Gomez 2014) 
provided the rationale for conducting a pediatric study 
using EGFR inhibitors. The use of erlotinib during and after 
local radiotherapy did not change the poor outcome of 
children with intracranial high grade gliomas (Qaddoumi 
et  al. 2014). The combination of erlotinib and rapamycin, 
an mTOR inhibitor, for recurrent low grade glioma patients 
was, in general, well tolerated but had questionable to no 
activity (Yalon et al. 2013). Clearly, erlotinib needs help.
Why erlotinib has not been more effective even in the pres-
ence of overexpression of EGFR, remains unclear (Zahonero 
and Sanchez-Gomez 2014) but a crucial question to answer. 
This paper now attempts a contribution to that answer.
Cells generally, and cancer cells specifically, are not pas-
sive recipients of therapeutic interventions. They react. As 
in the Preamble, interventions commonly and inherently 
generate reactions with effect opposing the original intent. 
In cancer treatment, this means reactions with potential 
to enhance tumor growth. This paper addresses one such 
compensatory growth-enhancing reaction- the elevation 
of interleukin-8 (IL-8) by erlotinib. The reviewed data will 
show how erlotinib-provoked IL-8 elevation has three neg-
ative effects on treatment efforts: (1) decreasing quality of 
life by generation of the neutrophilic erlotinib rash, (2) IL-8 
mediated enhanced migration or invasion of cancer cells in 
a similar manner as has been shown for neutrophils’ chem-
otaxis along an IL-8 gradient, and (3) enhanced neutrophil 
migration to and into tumors with ensuing growth contri-
bution by factors brought to tumors by these neutrophils.
Past research leads to a conclusion that the old anti-
Hansen’s disease sulfone antibiotic dapsone, when added 
to erlotinib, can be expected to mitigate all three IL-8-re-
lated erlotinib consequences that currently detract from 
erlotinib’s anti-cancer effectiveness.
The erlotinib rash
IL-8 (synonymous with CXCL-8) is an inflammation-
mediating, pro-angiogenic, ~8 kDa cytokine/chemokine, 
signaling via CXCR1 or CXCR2 receptors (Gales et  al. 
2013; Baggiolini et al. 1995). IL-8 is synthesized by nor-
mal cells, particularly keratinocytes, and by dozens of 
cancer types where it is involved in, and contributes to, 
several domains of cancer pathophysiology (Gales et  al. 
2013; Lippitz 2013). IL-8 is central to both normal and 
pathogenic angiogenesis (Desbaillets et al. 1997).
Development of rash during erlotinib treatment is a 
common occurrence. Typical erlotinib rashes are pleo-
morphic, appearing clinically as pruritic or nonpruritic 
papules, pustules, xerodermia, or paronychia (Kiyohara 
et  al. 2013). In confirming earlier studies of Nardone 
et  al., in 2012, Bangsgaard et  al. showed unequivocally 
that an iatrogenic erlotinib rash experimentally induced 
in healthy human volunteers was caused by IL-8 medi-
ated neutrophil infiltration (Nardone et  al. 2010; 
Bangsgaard et al. 2012). This would put erlotinib rashes 
solidly within the neutrophilic dermatoses’ category 
(Wallach and Vignon-Pennamen 2006)—a category in 
which dapsone has a long clinical history for being effec-
tive (Paniker and Levine 2001; Wozel and Blasum 2014; 
Cohen 2009).
Depending on dosing and study conditions, erlotinib 
rash can be seen in 75–90  % of treated patients, being 
severe in ~10  % (Tan and Chan 2009; Jia et  al. 2009; 
Rozensztajn et al. 2014) This rash is usually treated with 
topical antibiotics, meticulous skin care, minocycline and 
topical steroids (Kiyohara et  al. 2013). Development of 
an erlotinib rash confers clear but minor overall survival 
advantage when treating various cancers (Stepanski et al. 
2013; Kaburagi et al. 2013; Peereboom et al. 2010; Kiyo-
hara et  al. 2013; Aranda et  al. 2012; Petrelli et  al. 2012; 
Fiala et  al. 2013) with some indication that greater rash 
severity is correlated with slightly longer OS than lesser 
severity rashes (Kiyohara et  al. 2013; Rozensztajn et  al. 
2014; Petrelli et  al. 2012) A statistically significant asso-
ciation exists between higher erlotinib levels and greater 
likelihood of rash (Tiseo et al. 2014; Fukudo et al. 2013).
Erlotinib is not unique in stimulating IL-8 synthesis- 
many cancer chemotherapeutic drugs do. Urothelium 
exposed to doxorubicin at levels used in intravesical 
treatment triggered IL-8 synthesis (Kang et  al. 2013). 
Paclitaxel and temozolomide doubled IL-8 synthesis in 
melanoma cells (Luo et  al. 2012). 5-Fluorouracil (5-FU) 
induced IL-8 upregulation in prostate cancer cells, an 
effect mediated by IL-8 signaling at CXCR2 (Wilson 
et al. 2008a). Most importantly for the proposed role for 
dapsone, in that study direct 5-FU cytotoxicity reduc-
tion by that compensatory IL-8 increase could be miti-
gated by an experimental CXCR2 blocker (Wilson et al. 
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2008b), an effect expected to be duplicated by dapsone. 
Oxaliplatin induced increased IL-8 in metastatic prostate 
cells (Wilson et al. 2008a). Irradiation, 5-FU and cisplatin 
each individually triggered an increase in IL-8 in head 
and neck cancer cell lines (Reers et al. 2013). Topotecan 
increased IL-8 in breast cancer (Wan et al. 2012). Mela-
noma cells naturally secrete abnormally high levels of 
IL-8, levels that further increase after exposure to etopo-
side or doxorubicin (Merighi et  al. 2009). Even the sur-
gery of EOC resection can trigger systemic increase in 
IL-8 (Dong et  al. 2012). It is reasonable to assume that, 
were dapsone to indeed decrease IL-8 signaling, and its 
consequences, during erlotinib treatment, dapsone could 
find wide applicability in augmenting other cancer chem-
otherapies that engage compensatory increases in IL-8.
Thus, elevation of IL-8 seems to be a common-but not 
universal- attribute of cytotoxic chemotherapy drugs. 
Why rash is more common with erlotinib remains unex-
plained. IL-8 elevations in untreated cancer and its fur-
ther elevation by cancer chemotherapies are examples 
of the Preamble chess aphorism that indeed apply to 
medicine.
Dapsone
Dapsone is a 248  Da antibiotic introduced into clinical 
practice in the late 1940s and still used worldwide. Dap-
sone is active against, and used clinically to treat various 
species of Pneumocystis, Plasmodia, Toxoplasma, and 
Mycobacteria (Paniker and Levine 2001; Coleman 1993. 
Dapsone level is typically 2–5 microg/mL serum after 
single dose (Opravil et al. 1994; Swain et al. 1983). Time 
to Cmax is ~4 h, T ½ about 30 h, with significant variabil-
ity and enterohepatic circulation (Zuidema et  al. 1986). 
Therapeutic serum levels are thought to be between 0.5 
and 5 microg/mL when used in antibiotic and anti-pro-
tozoa roles (Zuidema et  al. 1986). Optimal blood levels 
when treating neutrophilic dermatoses have not been 
determined. CNS penetration of dapsone is excellent, 
cerebrospinal fluid levels reaching 50–100  % of serum 
levels (Rich and Mirochnick 1996), a particularly valu-
able attribute when treating glioblastoma. Although most 
sulfonamide allergic patients tolerate dapsone without 
problem, dapsone inhibits dihydrofolic acid synthesis by 
competing with para-aminobenzoic acid for the active 
site of dihydropteroate synthetase, preventing conversion 
of para-aminobenzoic acid to dihydrofolic acid (Coleman 
1993) as do sulfonamides.
Independently of its antibiotic attributes, dapsone is 
active in treating autoimmune bullous diseases (Piette 
and Werth 2012) and neutrophilic dermatoses (Paniker 
and Levine 2001; Wozel and Blasum 2014; Cohen 2009). 
In bullous pemphigoid dapsone stops bullae formation 
and often the rash but does not affect the underlying 
sub-epidermal auto-antibody fixation (Booth et al. 1992; 
Kasperkiewicz and Zillikens 2007; Shimanovich et  al. 
2004). But dapsone does stop the consequent IL-8 medi-
ated recruitment of neutrophils to areas of autoantibody 
deposition. Thereby dapsone stops bullae formation 
(Booth et al. 1992; Kasperkiewicz and Zillikens 2007; Shi-
manovich et al. 2004). Given the work of Nardone et al. 
and of Bangsgaard et  al. quoted above (Nardone et  al. 
2010; Bangsgaard et al. 2012) and the action of dapsone 
in autoimmune bullous diseases, in like manner dapsone 
will mitigate erlotinib rashes.
Of crucial importance to this intended use, dap-
sone inhibits LPS stimulated IL-8 production in human 
keratinocytes (Schmidt et  al. 2001). IL-8 synthesis was 
also reduced both in LPS stimulated bronchial epithelial 
cells in vitro (Kanoh et al. 2011), and in LPS stimulated 
peripheral blood mononuclear cells (Abe et  al. 2008). 
Dapsone quantitatively reduced mRNA expression of 
endothelin-1 (ET-1), macrophage inflammatory pro-
tein-1 alpha (MIP-1 alpha), and transforming growth 
factor-beta (TGF-beta) in a mouse model of paraquat 
lung injury (Cho et al. 2011). ET-1 (Kast 2009; Liu et al. 
2011; Patel and McKeage 2014; Paolillo et  al. 2010), 
MIP-1 (Fang et  al. 2011; Weigert et  al. 2009 and TGF-
beta (Hau et al. 2011; Joseph et al. 2013) are, all three to 
varying degrees, shown to contribute to many cancers’ 
growth and treatment resistance, including glioblastoma 
(Fang et al. 2011; Stiles et al. 1997) and EOC (Kast 2009; 
Vergara et  al. 2010). A crucial question for determining 
dapsone’s potential in the anti-cancer role would be to 
determine if these mRNA reductions are a primary effect 
of dapsone or a secondary effect to action at a paraquat-
specific trigger to these mRNA elevations.
Dapsone has already been suggested as an adjunct to 
glioblastoma treatment by blocking IL-8 directed migra-
tion of neutrophils into tumor, thereby lowering neu-
trophil-delivered VEGF to a growing glioblastoma (Kast 
et  al. 2011, 2012). As an ancillary benefit, by inhibiting 
5-lipoxygenase (5-LOX), dapsone diminishes leukotriene 
synthesis (Wozel and Blasum 2014; Wozel and Lehmann 
1995). 5-LOX products contribute to growth in glioblas-
toma (Morin et al. 2013; Ishii et al. 2009) and other can-
cers (Bishayee and Khuda-Bukhsh 2013; Meng et al. 2013; 
Wen et al. 2015).
IL‑8
IL-8 upregulation is a native feature of many cancers, 
forming an active growth facilitating factor for these 
cancers (Gales et al. 2013; Shi et al. 2001; Campbell et al. 
2013). Yet more central to cancer physiology, IL-8 forms 
a stronger growth enhancing role in the stem sub-pop-
ulation than in the non-stem population in breast can-
cer (Singh et al. 2013a, 2013b) hepatocellular carcinoma 
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(Tang et  al. 2012), squamous head/neck cancer (Chika-
matsu et  al. 2011), glioblastoma, (Infanger et  al. 2013; 
Bonavia et al. 2012) and others.
Exogenous IL-8 stimulated EOC cell line proliferation 
in vitro (Wang et al. 2005, 2011; Merritt et al. 2008; Wang 
et al. 2012). By immunohistochemistry only half of EOC 
patient biopsies were positive for high IL-8 expression, 
with higher expression correlating with shorter overall 
survival (Merritt et al. 2008). Although confirming EOC 
synthesis of IL-8 using immunohistochemistry of EOC 
surgical resection tissue, others found no relationship 
between staining intensity and OS (Browne et al. 2013).
By in vitro hybridization in EOC biopsies IL-8 mRNA 
was found to be overexpressed (Davidson et  al. 2003). 
EOC cell lines synthesize and secrete IL-8, with more 
IL-8 being synthesized in estrogen receptor negative cell 
lines, less in estrogen receptor positive lines (Davidson 
et al. 2003). Serum IL-8 levels were higher in EOC than 
in controls (Lokshin et  al. 2006; Autelitano et  al. 2012), 
with higher levels predicting shorter OS (Bertenshaw 
et  al. 2008; Dobrzycka et  al. 2013; Kassim et  al. 2004). 
EOC tumor associated macrophages have the ability to 
stimulate EOC cells’ IL-8 synthesis (Wang et  al. 2013). 
EOC migration and invasion is stimulated by omental 
adipocytes, an effect largely mediated by IL-8 (Nieman 
et al. 2011).
EOC cell migration along an IL-8 gradient (Ma et  al. 
2011) is reminiscent of similar findings of neutrophil 
chemotaxis along an IL-8 gradient. Since solid data shows 
dapsone blinding of neutrophils’ migration along an IL-8 
gradient, similar blinding by dapsone of EOC cells can be 
expected. IL-8 figures prominently in the typical intense 
neovascularization in EOC (Yang et al. 2010).
In vitro EOC resistance to cisplatin and paclitaxel is 
enhanced by exogenous IL-8 (Wang et al. 2011). Epineph-
rine or norepinephrine exposure resulted in more than 
doubling of IL-8 protein and mRNA in EOC cells, with 
even greater increases in the IL-8 promoter, effects that 
were all blocked by propranolol (Shahzad et al. 2010).
The importance of Cho et al’s demonstration of TGF-
beta mRNA decreases after dapsone (Cho et  al. 2011) 
meshes nicely with Serizawa et  al’s demonstration of 
enhancement of erlotinib’s effects on non-small cell lung 
cancer if TGF-beta is simultaneously inhibited (Serizawa 
et al. 2013). This also supports a trial of dapsone augmen-
tation of erlotinib.
Adding to the appeal of using dapsone to retard neu-
trophil migration to cancers are two further aspects. 
One: In two underappreciated but truly elegant papers, 
Werther et  al. (2002) and Svensen et  al. (2004) proved 
that circulating neutrophils deliver VEGF to rectal can-
cers. By measuring neutrophil number and VEGF con-
tent in the arterial supply and in the venous drainage of 
these tumors, they found 16 % of VEGF containing neu-
trophils entering the tumor do not exit it (Werther et al. 
2002; Svendsen et al. 2004). Also neutrophils are not just 
a source of VEGF (Kast et al. 2011, 2012; García-Román 
and Zentella-Dehesa 2013; Lee et al. 2002) and IL-8- they 
deliver other growth factors too.
Neutrophils are a prodigious source of multiple other 
cytokines and growth factors of importance in promoting 
cancer’s growth and treatment resistance (Lee et al. 2002; 
Scapini et  al. 2000; Kasama et  al. 2005). Two: During 
both normal and pathological angiogenesis endothelial 
IL-8 and neutrophils’ IL-8 have an interesting relation-
ship. When endothelium is exposed to IL-8 secreted by 
neutrophils this awakens and stimulates vessel endothe-
lium to synthesize IL-8, generating a stronger IL-8 gra-
dient along which neutrophils home, bringing yet more 
IL-8 to the site, thus forming a feedforward amplifica-
tion cycle first clearly identified by Garcia-Roman et  al. 
in 2002 (García-Román and Zentella-Dehesa 2013) and 
(Schruefer et al. 2005).
IL-8 synthesized by keratinocytes after minor wounds 
attracts neutrophils to the wound (Lan et al. 2013). High 
ambient glucose, as obtains in diabetes, increases such 
IL-8 mediated neutrophil migration to wound when 
neutrophil over-population delays rather than hastens 
wound healing (Lan et  al. 2013). Dapsone normalized 
wound healing in a diabetic rat model by reducing such 
excess neutrophil accumulation (Lan et al. 2013).
A little noted breakthrough in understanding glioblas-
toma pathophysiology came from a study showing that 
endothelial cells can upregulate their synthesis of IL-8 
in response to glioblastoma cells’ secreted IL-8, and vice 
versa (Infanger et  al. 2013), findings that replicate the 
feedforward system of Schruefer et  al. (2005) between 
neutrophils and endothelial cells, findings that again 
support the potential role for dapsone in glioblastoma 
treatment.
Glioblastoma (Infanger et al. 2013; Zhang et al. 2015), 
non-small cell lung cancer (Liu et  al. 2015; Khan et  al. 
(2015), ovarian cancer (Wang et  al. 2011; Browne et  al. 
2013; Stronach et al. 2015) and many other cancers’ (San-
mamed et al. 2014) cells synthesize IL-8 and express its 
receptor(s). IL-8 has specifically been recognized as a fac-
tor mediating erlotinib resistance in non-small cell lung 
cancer (Liu et  al. 2015). As Zhang et  al. suggest, IL-8 
would be a “novel therapeutic target for glioma invasion 
intervention” (Zhang et  al. 2015). Dapsone may provide 
such, resurrecting erlotinib usefulness for glioblastoma 
and other cancers.
Caveats
Erlotinib absorption is facilitated by gastric acid so use 
of proton pump inhibitors should be avoided. Tobacco 
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use limits erlotinib absorption so use of all tobacco 
products must be stopped. Dapsone’s primary metabo-
lite N-hydroxydapsone inhibits leukotriene chemotaxis 
and has other anti-inflammatory attributes (Wozel et al. 
1997) of potential benefit during cancer treatment, but 
not further discussed here.
Conclusions
This paper reviewed the growth promoting aspects of 
IL-8 in a few selected cancers and data showing how erlo-
tinib, a drug designed to- and in a limited way succeeded 
in decreasing cancer growth, can and often does increase 
IL-8 in skin. The data on neutrophils’ sine qua non role 
in generating the erlotinib rash implies a rash-mitigating 
role for dapsone. During clinical use in the neutrophilic 
dermatoses like bullous pemphigoid, dapsone blinds neu-
trophils to IL-8 chemotaxis, suggesting by extension that 
dapsone can ameliorate erlotinib rash, increasing toler-
ability and quality of life. The tumor growth enhancing 
effects of IL-8 itself and via neutrophil recruitment to 
a growing tumor were reviewed.  Effects expected to be 
partially thwarted by dapsone.
Perhaps the most pivotal, telling, and dramatic insight 
into erlotinib action, and of particular relevance to dap-
sone augmentation is the recent work of Takashima 
et  al. (Takashima et  al. 2012). A cohort of 76 erlotinib-
treated (150  mg/day) advanced, previously treated non-
small cell lung cancer patients developing a rash were 
divided into two groups—24 whose erlotinib dose was 
down-titrated to rash mitigation and 31 who were left 
at the rash-generating dose. Median OS was 566 days in 
the dose reduction, rash mitigation group but 202  days 
in the dose maintained, original dose group (Takashima 
et  al. 2012). Such a result would seem to contradict the 
many studies showing rash as a marginally favorable 
sign. If dose-related rash mitigation and longer OS is the 
result of decreasing compensatory IL-8 drive secondary 
to decreased erlotinib dose as the reviewed data suggest, 
then dapsone augmentation may well work by similarly 
decreasing IL-8 related growth drive and give erlotinib 
help it clearly needs (Zahonero and Sanchez-Gomez 
2014).
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